GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Burzynski Research Institute Inc (OTCPK:BZYR) » Definitions » Equity-to-Asset

Burzynski Research Institute (Burzynski Research Institute) Equity-to-Asset : -35.00 (As of Nov. 2023)


View and export this data going back to . Start your Free Trial

What is Burzynski Research Institute Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Burzynski Research Institute's Total Stockholders Equity for the quarter that ended in Nov. 2023 was $-0.04 Mil. Burzynski Research Institute's Total Assets for the quarter that ended in Nov. 2023 was $0.00 Mil.

The historical rank and industry rank for Burzynski Research Institute's Equity-to-Asset or its related term are showing as below:

BZYR' s Equity-to-Asset Range Over the Past 10 Years
Min: -128   Med: -16.25   Max: 0.71
Current: -35

During the past 13 years, the highest Equity to Asset Ratio of Burzynski Research Institute was 0.71. The lowest was -128.00. And the median was -16.25.

BZYR's Equity-to-Asset is ranked worse than
98.98% of 1561 companies
in the Biotechnology industry
Industry Median: 0.67 vs BZYR: -35.00

Burzynski Research Institute Equity-to-Asset Historical Data

The historical data trend for Burzynski Research Institute's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burzynski Research Institute Equity-to-Asset Chart

Burzynski Research Institute Annual Data
Trend Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.50 -7.65 -46.00 0.20 -7.00

Burzynski Research Institute Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.50 -7.00 -71.00 -2.00 -35.00

Competitive Comparison of Burzynski Research Institute's Equity-to-Asset

For the Biotechnology subindustry, Burzynski Research Institute's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Burzynski Research Institute's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Burzynski Research Institute's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Burzynski Research Institute's Equity-to-Asset falls into.



Burzynski Research Institute Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Burzynski Research Institute's Equity to Asset Ratio for the fiscal year that ended in Feb. 2023 is calculated as

Equity to Asset (A: Feb. 2023 )=Total Stockholders Equity/Total Assets
=-0.014/0.002
=

Burzynski Research Institute's Equity to Asset Ratio for the quarter that ended in Nov. 2023 is calculated as

Equity to Asset (Q: Nov. 2023 )=Total Stockholders Equity/Total Assets
=-0.035/0.001
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Burzynski Research Institute  (OTCPK:BZYR) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Burzynski Research Institute Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Burzynski Research Institute's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Burzynski Research Institute (Burzynski Research Institute) Business Description

Traded in Other Exchanges
N/A
Address
9432 Katy Freeway, Houston, TX, USA, 77055
Burzynski Research Institute Inc engages in the research, production, marketing, promotion, and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are used in the treatment of human cancer. Its pipeline development programs of the company include clinical trials for the treatment of a wide variety of cancers using only a combination of Antineoplastons A10 and AS2-1.
Executives
Monika Szopa-paszkowiak director 9432 KATY FWY #200, HOUSTON TX 77055
Frederick Richard Schiff director 9432 KATY FREEWAY, HOUSTON TX 77055
Barbara Burzynski director, 10 percent owner 9432 KATY FREEWAY, HOUSTON TX 77055
Carlton Hazlewood director 9432 KATY FREEWAY, HOUSTON TX 77055
Patryk Goscianski officer: Secretary and Treasurer 9432 KATY FREEWAY, HOUSTON TX 77055
Gregory Burzynski director 9432 KATY FREEWAY, HOUSTON TX 77055
Tomasz Janicki officer: VP of Clinical Trials 9432 KATY FREEWAY, HOUSTON TX 77055
Michael Driscoll director 9432 KATY FREEWAY, HOUSTON TX 77055
Stanislaw Burzynski director, 10 percent owner, officer: President 9432 KATY FREEWAY, HOUSTON TX 77055
Dudley Reece Anderson officer: Chief Financial Officer 9432 OLD KATY RD., SUITE 200, HOUSTON TX 77055

Burzynski Research Institute (Burzynski Research Institute) Headlines

No Headlines